

# Yoon's Cardiac Electrophysiology Lab

**Director: Namsik Yoon, M.D., Ph.D., Prof**

**ADDRESS:**

Heart Center, Chonnam National University Hospital,  
42 Jebong-ro, Dong-gu, Gwangju 61469 Korea

**E-mail:** [NSAIDs77@hitel.net](mailto:NSAIDs77@hitel.net), [yoonnamsik@gmail.com](mailto:yoonnamsik@gmail.com), [NSAIDs77@jnu.ac.kr](mailto:NSAIDs77@jnu.ac.kr)

**Fax:** (82) 62-225-6260

**Mobile Phone:** (82) 10-3065-1161,




**Biography**

- 2021 Director of Academic Affairs in Korean Heart Rhythm Society
- 2018 Visiting physician, Good Samaritan Hospital, LA, CA, USA
- 2013~2014, Postdoctoral fellowship, Masonic Medical Research Laboratory, Upstate Medical School, SUNY, NY, USA
- 2009 Chonnam National University Medical School, PhD
- 2007 Training course of clinical pharmacology in Kitasato University East Hospital, Japan
- 2006 Fellowship, Dept of Cardiology, Chonnam National University Hospital, Gwangju, Korea

**Scope:**

My major preoccupation has been research into sudden cardiac death and the electrophysiology of inherited cardiac arrhythmias such as Brugada syndrome, long QT syndrome, short QT syndrome, catecholaminergic polymorphic ventricular tachycardia, arrhythmogenic right ventricular dysplasia/cardiomyopathy. My work has led to the identification of novel mechanisms by which medications exert protective effects against adverse electrophysiological substrates underlying cardiac arrhythmias. These pre-clinical findings have provided opportunities for translational application, improving risk stratification for patients suffering from rare cardiac ion channelopathies and common cardiovascular diseases. I served as the Principal Investigator of population-based studies.

My team has successfully developed risk models (J wave syndrome model) to stratify patients who are at risk of adverse events and mortality. These models have been significantly improved by the established Langendorff model, wedge preparation model, small animal in-vivo, and large animal in-




vivo model.

**RESEARCH EXPERIENCE:**


- \* Recent Update in Out-of-Hospital Cardiac Arrests in Korea. Korean Circ J. 2021
- \* Meaning of Ventricular Arrhythmia Burden Reduction as a Marker of Ablation Success. Korean Circ J. 2021
- \* Socioeconomic Status and Outcomes in Heart Failure With Reduced Ejection Fraction From Asia. Circ Cardiovasc Qual Outcomes. 2021

- \* Right Ventricular Longitudinal Conduction Delay in Patients with Brugada Syndrome. J Korean Med Sci. 2021
- \* Cisplatin-induced Atrioventricular Block Requiring a Pacemaker: Two Case Reports and a Literature Review. Electrolyte Blood Press. 2020



- \* Positive chronotropic effects of theophylline and cilostazol in patients with symptomatic sick sinus syndrome who have declined permanent pacing. Rev Cardiovasc Med. 2020
- \* Transmural conduction time in an early repolarization syndrome model. Experimental and Therapeutic Medicine 2020.
- \* Radiofrequency catheter ablation without radiation exposure in a 13th week pregnant woman with Wolff-Parkinson-White syndrome. Rev Cardiovasc Med. 2020 Jun 30;21(2):303-307


- \* Experimental verification of the value of the Tpeak -Tend interval in ventricular arrhythmia inducibility in an early repolarization syndrome model. J Cardiovasc Electrophysiol. 2019 Oct;30(10):2098-2105.



- \* Epicardial Substrate as a Target for Radiofrequency Ablation in an Experimental Model of Early Repolarization Syndrome. Circ Arrhythm Electrophysiol. 2018 Sep;11(9):e006511.


- \* Tpeak-Tend interval during therapeutic hypothermia can predict upcoming ventricular fibrillation in subjects with aborted arrhythmic sudden cardiac death; 3 years follow-up results. Europace. 2017 Dec 1;19(suppl\_4):iv17-iv24

- \* Mechanisms Underlying Epicardial Radiofrequency Ablation to Suppress Arrhythmogenesis in Experimental Models of Brugada Syndrome. JACC Clin Electrophysiol. 2017 Apr;3(4):353-363



- \* Pacemaker Lead Fracture Treated with Splinting and Venoplasty. The Korean Journal of Medicine 2015;88(2): 197-201.

\* Beneficial effects of an angiotensin-II receptor blocker on structural atrial reverse-remodeling in a rat model of ischemic heart failure. *Exp Ther Med.* 2013 Apr;5(4):1009-1016. doi: 10.3892/etm.2013.920. Epub 2013 Jan 23.



#### PAST CLINICAL RESEARCH ISSUE:

- \* S44121 (Phase II): Evaluation of the anti-arrhythmic effects of 3 oral dosages of S44121 versus placebo in patients with chronic heart failure and left ventricular systolic dysfunction at risk for ventricular arrhythmia A 12-week, randomized, double-blind, parallel-group, placebo controlled, international multicentre study (CL2-44121-006)
- \* CKD-828 (Phase III): A Randomized, Double-blind, Multi-center, Phase 3 Trial to Evaluate the Efficacy and Safety of a Fixed Dose Combination of S-Amlodipine and Telmisartan(CKD-828) versus S-Amlodipine Monotherapy in Hypertensive Patients Inadequately Controlled by S-Amlodipine Monotherapy
- \* PALLAS (Phase III): A randomized, double blind, placebo controlled, parallel group trial for assessing the clinical benefit of Dronedarone 400mg BID on top of standard therapy in patients with permanent atrial fibrillation and additional factors, Role: Sub-I
- \* MK6621 (Phase III): A Phase III, Prospective, Randomized, Double-Blind, Placebo-Controlled Multicenter Study to Evaluate the Efficacy and Safety of MK-6621 in Patients with Atrial Fibrillation , Role: Sub-I
- \* CKD-828 (Phase II): A Randomized, Double-Blind, Multi-center, Multi-factorial, Phase 2 Trial to to Evaluate the Efficacy and Safety of S-Amlodipine/Telmisartan Combined or Alone and Select Better Dose of CKD-828 in Patients with Essential Hypertension , Role: PI
- \* GARFIELD (Phase IV): Prospective, multi centre, international registry of male and female patients newly diagnosed with atrial fibrillation , Role: Sub-I
- \* OPAL-2 (Phase II): Double-Blind, Double-Dummy, Randomized, Parallel Group Dose Finding Study to Investigate the Safety and Tolerability of YM150 in Subjects with Non-Valvular Atrial Fibrillation and to Compare the Safety and Tolerability with Warfarin, Role: Sub-I
- \* RecordAF-AP (Phase IV): Registry on Cardiac rhythm disorders: an international, observational, prospective survey assessing the control of Atrial Fibrillation in Asia Pacific, Role: Sub-I
- \* RELY-ABLE (Phase III): Long term multi-center extension of dabigatran treatment in patients with atrial fibrillation who completed the RE-LY trial and a cluster randomized trial to assess the effect of a knowledge translation intervention on patient outcomes, Role: Sub-I
- \* AVERROES (Phase III): Apixaban Versus Acetylsalicylic Acid (ASA) to Prevent Stroke in Atrial

Fibrillation Patient Who Have Failed or are Unsuitable for Vitamin K Antagonist Treatment: A Randomized Double Blind Trial, Role: Sub-I

- \* Borialis-AF (Phase III): A multicenter, randomized, double-blind, assessor-blind, noninferiority study comparing the efficacy and safety of once-weekly subcutaneous biotinylated idraparinux (SSR126517E) with oral adjusted-dose warfarin in the prevention of stroke and systemic thromboembolic events in patients with atrial fibrillation, Role: Sub-I
- \* DIONYSOS (Phase III): Efficacy & Safety of Dronedaronone Versus Amiodarone for the Maintenance of Sinus Rhythm in Patients With Atrial Fibrillation, Role: Sub-I
- \* SEPIA-ACS1 /TIMI 42 (Phase III): A randomized, double-blind, triple-dummy, dose-ranging study, including an active control of unfractionated heparin and eptifibatide, to evaluate the clinical efficacy and safety of otamixaban, in patients with non-ST elevation acute coronary syndrome and planned early invasive strategy, Role: Sub-I